Alcimed Foundation for Rare Diseases

In December 2023 Alcimed launched its corporate foundation “Alcimed Foundation for Rare Diseases” to help patients, patient families and associations for patients suffering from the rarest diseases by enabling them to benefit free of charge from the expertise of its team.

The foundation’s objective

Alcimed has acquired recognized expertise in the field of rare diseases and through the foundation wishes to make its teams and skills available, free of charge, to patients, patient families and associations for patients suffering from the rarest diseases. This is our way of helping patients and their families who no one else can support.

 

Alcimed teams at the service of patients

The foundation is intended to be a continuation of Alcimed’s actions, recognized for its expertise in the field of rare diseases among players in the sector.

“This project makes particular sense for our teams, who want to help patients and their families directly”, explains Valérie Kniazeff, President of Alcimed and of the new foundation.

 

A battle encompassing a wide range of actions

The foundation will support those affected by the rarest of these diseases through the help of Alcimed teams:

  • conducting state-of-the-art analyses on the concerned diseases
  • analyzing the level of care available for these diseases
  • identifying experts, treatments and clinical studies in progress worldwide
  • supporting the development or enrolment of patients in new clinical trials
  • identifying solutions to improve patients’ quality of life
  • and much more…

 

The foundation’s scope of action

  • Who is eligible?
    • Patients, patient families and associations for patients affected by rare diseases who today receive little attention or have limited resources,
    • patients suffering from the rarest diseases for which medical needs are the least covered,
    • and who are based in France (the foundation’s current geographical perimeter).

 

  • Who is not eligible? Foundations, associations other than patient associations, private companies, institutions, for-profit healthcare organizations.